These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36968656)

  • 1. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.
    Hegarty R; Kyrana E; Fitzpatrick E; Dhawan A
    Ther Adv Endocrinol Metab; 2023; 14():20420188231160388. PubMed ID: 36968656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.
    Rupasinghe K; Hind J; Hegarty R
    J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
    Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
    J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.
    Kaya E; Yilmaz Y
    Ther Adv Endocrinol Metab; 2022; 13():20420188221139650. PubMed ID: 36533185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
    Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
    Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAFLD: Renovation of clinical practice and disease awareness of fatty liver.
    Kawaguchi T; Tsutsumi T; Nakano D; Torimura T
    Hepatol Res; 2022 May; 52(5):422-432. PubMed ID: 34472683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAFLD: a multisystem disease.
    Pipitone RM; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Pennisi G; Grimaudo S; Petta S
    Ther Adv Endocrinol Metab; 2023; 14():20420188221145549. PubMed ID: 36726391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
    Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis.
    Liu J; Mu C; Li K; Luo H; Liu Y; Li Z
    Int J Public Health; 2021; 66():1604371. PubMed ID: 34690666
    [No Abstract]   [Full Text] [Related]  

  • 16. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    Nan Y; An J; Bao J; Chen H; Chen Y; Ding H; Dou X; Duan Z; Fan J; Gao Y; Han T; Han Y; Hu P; Huang Y; Huang Y; Jia J; Jiang J; Jiang Y; Li J; Li J; Li R; Li S; Li W; Li Y; Lin S; Liu J; Liu S; Lu L; Lu Q; Luo X; Ma X; Rao H; Ren H; Ren W; Shang J; Shi L; Su M; Wang B; Wang R; Wei L; Wen Z; Wu B; Wu J; Xin S; Xing H; Xu J; Yan M; Yang J; Yang J; Yang L; Yang Y; Yu Y; Zhang L; Zhang L; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhao S; Zheng H; Zhou Y; Zhou Y; Zhuang H; Zuo W; Xu X; Qiao L
    J Hepatol; 2021 Aug; 75(2):454-461. PubMed ID: 34019941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.
    Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W
    Front Nutr; 2022; 9():906511. PubMed ID: 35782947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
    Kim KS; Hong S; Ahn HY; Park CY
    Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.